Windlas Biotech Ltd
Windlas Biotech Ltd (WINDLAS) last traded at ₹988, a market capitalisation of ₹2,038 crore, on a P/E of 30.7. Over the past 52 weeks the stock has ranged between ₹697 and ₹1,036. Windlas Biotech Ltd last reported results for the quarter ended Mar 2026, with sales of ₹238 crore and net profit of ₹16 crore. Figures are as of 25 Aug 2026 and are not real time.
Windlas Biotech Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Windlas Biotech Ltd quarterly results
In the quarter ended Mar 2026, sales were ₹238 cr, up 17.2% from ₹203 cr a year earlier. Net profit was ₹16 cr, up 0.0% year on year.
| ₹ crore | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 175 | 187 | 195 | 203 | 210 | 222 | 233 | 238 |
| Expenses | 154 | 164 | 170 | 177 | 184 | 194 | 209 | 213 |
| Operating profit | 21 | 23 | 25 | 26 | 27 | 29 | 24 | 25 |
| OPM % | 12% | 12% | 13% | 13% | 13% | 13% | 10% | 11% |
| Other income | 4 | 5 | 4 | 5 | 5 | 4 | 5 | 4 |
| Interest | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 6 | 6 | 7 | 8 | 7 | 8 | 8 | 8 |
| Profit before tax | 18 | 20 | 20 | 21 | 23 | 24 | 20 | 20 |
| Tax % | 26% | 23% | 23% | 22% | 24% | 25% | 25% | 21% |
| Net profit | 13 | 16 | 16 | 16 | 18 | 18 | 15 | 16 |
| EPS (₹) | 6.45 | 7.49 | 7.45 | 7.77 | 8.43 | 8.45 | 7.12 | 7.58 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Windlas Biotech Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Sales | 428 | 466 | 513 | 631 | 760 | 904 |
| Operating profit | 55 | 52 | 60 | 78 | 94 | 105 |
| OPM % | 13% | 11% | 12% | 12% | 12% | 12% |
| Net profit | 16 | 38 | 43 | 58 | 61 | 66 |
| EPS (₹) | 24.69 | 17.48 | 20.04 | 27.98 | 29.10 | 31.49 |
TTM is the trailing twelve months to the most recent quarter.
Windlas Biotech Ltd growth and returns
- 10 Years
- %
- 5 Years
- 16%
- 3 Years
- 21%
- TTM
- 19%
- 10 Years
- %
- 5 Years
- 16%
- 3 Years
- 17%
- TTM
- 9%
- 10 Years
- %
- 5 Years
- 24%
- 3 Years
- 40%
- 1 Year
- -1%
- 10 Years
- %
- 5 Years
- 12%
- 3 Years
- 13%
- Last Year
- 12%
Windlas Biotech Ltd shareholding pattern
Promoters held 63.31% at Jun 2026, up from 62.34% at Jun 2025. FIIs 2.04% and DIIs 9.84%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 62.51% | 62.51% | 62.34% | 62.34% | 61.98% | 61.98% | 61.90% | 63.31% |
| FIIs | 2.00% | 1.55% | 1.52% | 1.44% | 1.11% | 0.93% | 0.60% | 2.04% |
| DIIs | 9.58% | 10.26% | 10.89% | 11.22% | 11.44% | 11.44% | 11.80% | 9.84% |
| Public | 25.91% | 25.67% | 25.25% | 25.01% | 25.48% | 25.64% | 25.69% | 24.80% |
| No. of shareholders | 45,706 | 46,590 | 46,383 | 45,887 | 45,433 | 45,461 | 44,769 | 44,996 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Windlas Biotech Ltd corporate filings
- Q1 FY27 Earnings Conference Call Transcript enclosed.Company Updatehigh impact
Cruxal's analysis: Windlas Biotech Limited delivered its 14th consecutive quarter of record revenue…
Read the full analysis - Audio Recording Q1 conference callCompany Updatelow impact
Cruxal's analysis: Windlas Biotech has made the audio recording of its Q1 conference call available to the…
Read the full analysis - Press release titled 'Windlas Biotech Limited Reports its Q1 FY27 Financial Results'Company Updatehigh impact
Cruxal's analysis: Windlas Biotech Limited achieved its 14th consecutive quarter of record revenue, reaching…
Read the full analysis - Investor Presentation - Q1 FY27 enclosedCompany Updatehigh impact
Cruxal's analysis: Windlas Biotech Limited has announced its Q1 FY27 financial results, achieving a record…
Read the full analysis - approval of the Unaudited Standalone Financial Results for the Quarter ended June 30, 2026.Board Meetinghigh impact
Cruxal's analysis: Windlas Biotech Limited reported a robust performance for the quarter ended June 30…
Read the full analysis - Schedule of Conference Call to discuss financial performance for quarter ended June 30, 2026Company Updatelow impact
Cruxal's analysis: Windlas Biotech has announced a conference call to discuss its financial performance for…
Read the full analysis - Schedule of Conference Call to discuss financial performance for quarter ended June 30, 2026Company Updatelow impact
Cruxal's analysis: Windlas Biotech Ltd has issued an intimation regarding a conference call to discuss its…
Read the full analysis - Windlas Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve Notice is hereby given that ....Board Meetinglow impact
Cruxal's analysis: Windlas Biotech Limited has announced that its Board of Directors will convene a meeting…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Windlas Biotech Ltd
Cruxal reads every Windlas Biotech Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.